Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Congress 2022 | JAK2 V617F VAF as a diagnostic and prognostic marker for polycythemia vera and thrombosis risk

Alison Moliterno • 31 Oct 2022
MPN Congress 2022
Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases

Alison Moliterno, MD, Johns Hopkins Medicine, Baltimore, MD, discusses the association between JAK2 V617F variant allele fraction (VAF), clinical phenotype, and venous thrombosis risk in patients with polycythemia vera (PV), discussing its role as a prognostic and diagnostic marker in this disease. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting with Pharmessentia and Protagonist

More from Alison Moliterno

JAK2V617F VAF: clinical significance and applications in polycythemia vera
Alison Moliterno • 24 Nov 2022
3:19
Targeting JAK2 V617F VAF in polycythemia vera & the efficacy of ropeginterferon alfa-2b
Alison Moliterno • 31 Oct 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals